Vaxcyte, Inc. (PCVX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $46.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 12.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its XpressCF cell-free protein synthesis platform. It has no product revenue; the company had a net loss of $766.6M in 2025 and an accumulated deficit of $2.2B,... Read more
Sell if holding. Engine safety override at $46.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 12.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Vaxcyte, Inc.
Latest news
- NEWS Vaxcyte Announces First Patient Enrollment In Phase 1 Study Evaluating Group A Streptococcus Vaccine VAX-A1 — benzinga Jun 2, 2026 positive
- NEWS Top 3 Health Care Stocks You'll Regret Missing In May — benzinga May 26, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate — benzinga May 6, 2026 negative
Generated 2026-06-09T22:21:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineVAX-31 PCV franchise10-K Item 1A: 'Our business and future success depends on our ability to successfully develop, obtain regulatory approval of, and then commercialize our PCV candidates, which include VAX-31, our 31-valent clinical PCV candidate'
- HIGHSupplierLonza10-K Item 1: 'We have access to substantial manufacturing resources through our contract manufacturer, Lonza, that we believe can facilitate an independent path to market.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $46.85: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 12.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $44.20. Score 5.0/10, moderate confidence.
Take-profit target: $94.83 (+102.0% upside). Prior stop was $44.20. Stop-loss: $44.20.
Concentration risk — Pipeline: VAX-31 PCV franchise; Concentration risk — Supplier: Lonza; Quality below floor (1.2 < 4.0).
Vaxcyte, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover PCVX with a consensus score of 4.3/5. Average price target: $109.
What does Vaxcyte, Inc. do?Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its...
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (PCVs) using its XpressCF cell-free protein synthesis platform. It has no product revenue; the company had a net loss of $766.6M in 2025 and an accumulated deficit of $2.2B, funded by $2.4B in cash and investments as of December 31, 2025.